Navigation Links
Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
Date:4/8/2013

te blood cells. CLL is a B cell cancer that originates in the bone marrow. Approximately 16,000 patients in the US are diagnosed each year with CLL. The prevalence of CLL is approximately 113,000 in the US. The disease is a chronic disease of the elderly with an average survival of about 5 years. Patients commonly receive multiple lines of treatment over the course of their disease. CLL and Small lymphocytic lymphoma (SLL) are considered the same underlying disease. SLL is a disease that is limited to the lymph nodes.

About Ibrutinib

Janssen Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement in December 2011 to co-develop and co-commercialize ibrutinib. Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulation of apoptosis, adhesion, and cell migration and homing. Through these multiple signals, BTK regulation helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a micro environment necessary for survival.

The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma. To date five Phase III trials have been initiated with ibrutinib and a total of 26 trials are currently registered on www.clinicaltrials.gov.

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that d
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Nektar Therapeutics (NASDAQ: ... positive results from its Phase 3 pivotal clinical ... recombinant factor VIII (rFVIII) treatment for hemophilia A ... its primary endpoint in reducing annualized bleed rates ... on-demand arm. Top-line results from the ...
(Date:8/21/2014)... The spinal column is one of the most delicate and ... from the brain through the column control many key functions ... here can be life altering, and leave the victim in ... body. Though back injury and disease can have an intensely ... available to make things better than ever before. Laser ...
(Date:8/21/2014)... 21, 2014 /CNW/ - Eisai Limited is pleased to support ... first-of-its-kind comic book available in Canada . ... specifically to educate children and their parents about epilepsy, the ... affecting more than 300,000 Canadians. Eisai is guided by a ... in which the patient is central – there was a ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... N.J., Feb. 3, 2011 BioNeutral Group, Inc. (OTC ... science technology-based company, today announced the formation of BioNeutral ... Inc., and the appointment of Frank Battafarano as the ... BioNeutral Services will market and distribute a ...
... 2011 A VANIR Pharmaceuticals, Inc. ... the three months ended December 31, 2010. For the ... $12.1 million, or $0.11 loss per share, compared with a net ... same period in fiscal 2010. Net revenues consisting primarily of royalty ...
Cached Medicine Technology:BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc. 2BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc. 3AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 2AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 3AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 4AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 5AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results 6
(Date:8/22/2014)... August 22, 2014 Ticket Down ... in Kalamazoo, New Orleans, Albuquerque and Rapid City. For ... “Long Island Medium,” Theresa Caputo, allows just that. Caputo was ... is part of a close knit family who began to ... a spiritual healer, realized she had a chance to do ...
(Date:8/22/2014)... “Dr. Luciana Show – Aging and Falling” ... Luciana, is finding it challenging to stay on top of ... of hundreds of students, so the editing of the episodes ... completed, and she recently entered it into the festival circuit. ... her husband, actor/screenwriter Gregory Graham , the aging and ...
(Date:8/22/2014)... the leading pan-European organisation representing medical oncology professionals, ... receiving the Society,s esteemed annual awards. The awards ... and Peter Boyle on the occasion of the ... Carsten Bokemeyer will receive the ESMO Award for ... discovery into real benefit at patient level. 1 ...
(Date:8/22/2014)... Each year approx. 265,000 Danes are acutely admitted to ... from Aarhus University and Aarhus University Hospital now shows ... fourth patient are sent home again without receiving ... the acute hospitalisation., "Naturally, there is no need for ... that there is a serious illness. So some patients ...
(Date:8/22/2014)... of Alzheimer,s disease can be slowed and some ... that is found in pomegranate. Also, the ... arthritis and Parkinson,s disease could be reduced, according ... by University of Huddersfield scientist Dr Olumayokun Olajide, ... products. , Now, a new phase of research ...
Breaking Medicine News(10 mins):Health News:Theresa Caputo Tickets in Kalamazoo at Wings Stadium, Saenger Theatre in New Orleans, Kiva Auditorium in Albuquerque and Rapid City at Don Barnett Arena Now Available 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:Many patients are discharged without a diagnosis 2Health News:Research underway to create pomegranate drug to stem Alzheimer's and Parkinson's 2
... and TORONTO, March 4 /PRNewswire/ - Affinium Pharmaceuticals,today ... healthy subjects in,a Phase I study of AFN-1252, ... class of fatty acid biosyntheis inhibitors. The study ... of a single,escalating oral dose. Affinium believes that ...
... , The doctoral thesis of Isaac Manuel lvarez Ruiz ... Signal Theory, Telematics, and Communication , and Department of Surgery ... and directed by Professors ngel de la Torre Vega ... work includes improving the acquisition of Compound Action Potential records, carrying ...
... of Health,Dr. Calvin B. Johnson today met with ... discuss Governor Edward G. Rendell,s plan to,provide access ... uninsured,adults through his "Cover All Pennsylvanians" proposal., ... prevent disease,successfully manage chronic diseases such as diabetes ...
... fleet golf car and the role of MES, ... execution systems (MES) for the integrated enterprise,announced today that ... E-Z-GO Fleet Golf Car: Integrating Manufacturing,Execution with New Product ... March 6, 2008 at 2:00 p.m. EST., During ...
... retained 1 year after therapy , , TUESDAY, March 4 ... shows promise in adults, say American and Chinese researchers ... , Lazy eye, also known as amblyopia, has been ... condition, especially those in developing countries, are diagnosed too ...
... Promotes National Kidney Month Programs to,Combat Spread of ... WASHINGTON, March 4 DaVita Patient Citizens,(DPC) ... more than 22,000,dialysis and pre-dialysis patients and family ... all dialysis patients through education and,advocacy -- enthusiastically ...
Cached Medicine News:Health News:Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic 2Health News:Design of a new system that improves hearing in patients who carry a cochlear implant 2Health News:Design of a new system that improves hearing in patients who carry a cochlear implant 3Health News:Health Secretary's Statewide Tour to Discuss Health Insurance for All Pennsylvanians Makes Stop in Cambria County 2Health News:E-Z-GO and Visiprise to Participate in New Product Introduction Event with IndustryWeek 2Health News:E-Z-GO and Visiprise to Participate in New Product Introduction Event with IndustryWeek 3Health News:New Treatment for 'Lazy Eye' Shows Promise 2Health News:Kidney Patient Advocacy Community Joins National Effort to Raise Awareness about Health Crisis Impacting more than 26 Million Americans 2
Mounted on a remarkably lightweight and,flexible cotton headband with crown strap,the Sport is fully adjustable....
... putty is a product of AlloSource, ... in human tissue processing, and Interpore ... technology. InterGro combines AlloGro DBM ... to deliver a unique bone graft ...
... bone content (93% by volume) of any ... excellent handling characteristics, which will enhance any ... alone or as a graft extender for ... The high molecular weight biocompatible carrier allows ...
... DS Strep A is a qualitative assay for ... swabs. The ICON DS Strep A test excels ... rare and low positive colonization samples. This CLIA ... outstanding performance, ICON DS Strep A leaves little ...
Medicine Products: